[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-378718-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-378718-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","systemic-treatment-for-metastatic-colorectal-cancer-minireviews","Systemic treatment for metastatic colorectal cancer - MINIREVIEWS","","Significant progress has been achieved in the treatment of metastatic colorectal cancer (mCRC) over the past two decades, with many options now available for first-line care. Advances in next-generation sequencing and whole-exome sequencing have enabled the discovery of prognostic and predictive biomarkers, supporting more customized, personalized approaches. Appropriate adjuvant selection depends on tumor stage, high-risk pathology, microsatellite instability status, patient age, and performance status. Chemotherapy, targeted therapy, and immunotherapy remain key systemic strategies, and molecular and practical aspects are reviewed.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/systemic-treatment-for-metastatic-colorectal-cancer-minireviews/378718/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/systemic-treatment-for-metastatic-colorectal-cancer-minireviews/378718.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the main systemic treatment approaches for metastatic colorectal cancer (mCRC)?","Question",{"text":63,"@type":64},"Chemotherapy, targeted therapy, and immunotherapy are described as the main systemic treatments for mCRC patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do molecular technologies support personalized medicine in mCRC?",{"text":68,"@type":64},"Genomic profiling helps identify prognostic and predictive biomarkers, enabling treatment selection tailored to tumor biology and improving who can benefit from therapy while reducing exposure to ineffective medicines.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors influence appropriate adjuvant treatment selection for mCRC?",{"text":72,"@type":64},"Treatment decisions depend on tumor stage, high-risk pathologic characteristics, microsatellite instability status, patient age, and performance status.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},378718,1791314337,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","| W | J | G | World Journal of\u003Cbr>Gastroenterology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Gastroenterol 2023 March 14; 29(10): 1569-1588  \nDOI: 10.3748/wjg.v29.i10.1569 ISSN 1007-9327 (print) ISSN 2219-2840 (online)  \n\n| Systemic treatment for metastatic colorectal cancer\u003Cbr>Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana | MINIREVIEWS |\n| --- | --- |\n\nSpecialty type: Gastroenterology and hepatology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s scientific quality classification  \nGrade A (Excellent): 0  \nGrade B (Very good): B, B  \nGrade C (Good): 0  \nGrade D (Fair): 0  \nGrade E (Poor): 0  \nP-Reviewer: Luo Y, China; Wang Z, China  \nReceived: November 29, 2022  \nPeer-review started: November 29, 2022  \nFirst decision: February 8, 2023  \nRevised: February 16, 2023  \nAccepted: February 27, 2023  \nArticle in press: February 27, 2023  \nPublished online: March 14, 2023  \nWattana Leowattana, Pathomthep Leowattana, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand  \nTawithep Leowattana, Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Bangkok 10110, Thailand  \nCorresponding author: Wattana Leowattana, BMed, MD, MSc, PhD, Full Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi Road, Bangkok 10400, [Thailand.](Thailand. wattana.leo@mahidol.ac.th)[ wattana.leo@mahidol.ac.th](Thailand. wattana.leo@mahidol.ac.th)  \nAbstract  \nSignificant progress has been achieved in the treatment of metastatic colorectal cancer (mCRC) patients during the last 20 years. There are currently numerous treatments available for the first-line treatment of mCRC. Sophisticated molecular technologies have been developed to reveal novel prognostic and predictive biomarkers for CRC. The development of next-generation sequencing and wholeexome sequencing, which are strong new tools for the discovery of predictive molecular biomarkers to facilitate the delivery of customized treatment, has resulted in tremendous breakthroughs in DNA sequencing technology in recent years. The appropriate adjuvant treatments for mCRC patients are determined by the tumor stage, presence of high-risk pathologic characteristics, microsatellite instability status, patient age, and performance status. Chemotherapy, targeted therapy, and immunotherapy are the main systemic treatments for patients with mCRC. Despite the fact that these novel treatment choices have increased overall survival for mCRC, survival remains optimal for individuals with non-metastatic disease. The molecular technologies currently being used to support our ability to practice personalized medicine; the practical aspects of applying molecular biomarkers to regular clinical practice; and the evolution of chemotherapy, targeted therapy, and immunotherapy strategies for the treatment of mCRC in the front-line setting are all reviewed here.  \nKey Words: Systemic treatment; Metastatic colorectal cancer; Personalized medicine; Biomarkers; Chemotherapy; Targeted therapy; Immunotherapy  \n©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.  \n WJG  [https://www.wjgnet.com](https://www.wjgnet.com) 1569 March 14, 2023  Volume 29  Issue 10   \nLeowattana W et al. Systemic treatment for mCRC  \nCore Tip: Advances in the molecular profiling of metastatic colorectal cancer allow treatment to be tailored to the biologic characteristics of the tumor for certain patient subgroups. Although cures are still rare, more people can expect to live longer. Genomic profiling enables therapy selection, allowing more individuals to benefit while exposing fewer to the harm of ineffective medicines. An important component in determining treatment results is the choice of an effective first-line therapy, which s","cbCairq8tOkBU8Zg","https://ap.wps.com/l/cbCairq8tOkBU8Zg","pdf",1677587,21,"English","# Abstract\n# Key Words\n# Core Tip\n# Background and Epidemiology of Colorectal Cancer","[{\"question\":\"What are the main systemic treatment approaches for metastatic colorectal cancer (mCRC)?\",\"answer\":\"Chemotherapy, targeted therapy, and immunotherapy are described as the main systemic treatments for mCRC patients.\"},{\"question\":\"How do molecular technologies support personalized medicine in mCRC?\",\"answer\":\"Genomic profiling helps identify prognostic and predictive biomarkers, enabling treatment selection tailored to tumor biology and improving who can benefit from therapy while reducing exposure to ineffective medicines.\"},{\"question\":\"Which factors influence appropriate adjuvant treatment selection for mCRC?\",\"answer\":\"Treatment decisions depend on tumor stage, high-risk pathologic characteristics, microsatellite instability status, patient age, and performance status.\"}]","Systemic treatment for metastatic colorectal cancer - MINIREVIEWS | PDF",1790232074,53]